Spontaneous acceptance of liver allografts occurs in several species. However, tolerance is rare in human transplant patients even though rejection is relatively easily reversed. Histological features of acute rejection in liver transplantation are similar to those in other organs. Nevertheless, mechanisms of rejection of liver transplants may differ in degrees and cellular involvement. Liver-specific cell populations, such as Kupffer cells (KCs), liver sinusoidal epithelial cells (LSECs), and hepatic stellate cells (HSCs), may contribute to liver tolerogenicity. Other mechanisms, such as microchimerism, soluble major histocompatibility complex (MHC molecules), donor human leukocyte antigen (HLA)-C genotype, and regulatory T cells, may participate in inducing tolerance. The low incidence of hyperacute or antibody-mediated rejection in liver might be linked to the infrequency of chronic rejection of liver transplants. Understanding the mechanisms of liver transplant rejection/tolerance and the availability of better immune monitoring could help develop strategies to recognize tolerance and reduce rejection.
IMMUNOLOGICAL CHARACTERISTICS OF LIVER TRANSPLANTATION
Since the earliest experience of experimental liver transplantation in animals and humans, it was apparent that the liver enjoyed immunological privilege compared with other transplanted organs. For example, pig liver transplants performed by Roy Calne experienced spontaneous tolerance despite rejection of renal transplants in the same model. 1 Flye et al, who also performed outbred pig liver transplants, did not see such consistent tolerance, explaining the difference on the basis of the likely greater genetic disparity in American swine. 2 Rat liver transplants in certain genetic combinations experienced tolerance, although in other combinations (high responder combinations in renal transplantation) rejected acutely. [3] [4] [5] [6] Most strain combinations of mice experience spontaneous tolerance following liver transplant surgery.
In contrast, human liver transplantation was plagued by frequent rejection during the precyclosporine era. Even after the introduction of calcineurin inhibitors, the historic rejection rates after human liver transplants were in the range of 50 to 75%; however, recent data from the U.S. Scientific Registry for Transplant Recipients suggest that the rejection rate is currently in the range of 30%. 7 Although there are examples of patients with long-surviving liver transplants who are not taking immunosuppressive drugs (i.e., tolerance), the number and relative frequency of such patients is remarkably low considering the number of papers and talks claiming that liver transplants can become tolerant with ease in humans.
What is clear is that acute rejection in liver transplant patients can be relatively easily reversed, with very rare graft loss due to acute rejection in patients receiving immunosuppressive therapy. The damage to liver parenchyma caused by acute rejection heals and does not leave long-lasting injury in general. Compared with other transplanted organs, alloantibody does not cause obvious graft injury nearly to the extent seen in, for instance, kidney transplantation. Although the liver may undergo hyperacute rejection by preformed antidonor alloantibody, 8, 9 such an event is rare in humans and requires a highly sensitized recipient. The role of alloantibody long term has not been well studied in human liver transplantation, and a potential contribution to chronic rejection has not been established, unlike the experience with lung, heart, and kidney transplants. [10] [11] [12] [13] Furthermore, the incidence of chronic rejection in longsurviving human liver transplantation is low, $2%, compared with frequent occurrence in kidney transplantation (at least 20%). No satisfactory explanation has been offered for many of these observations, thus making the liver a fascinating topic of study in transplant immunology.
Another unique observation about liver transplantation is that the donor liver is cotransplanted with a substantial mass of donor cells having hematopoietic and immune function themselves. This makes the liver capable of mounting a graft-versus-host (GVH) response, which is more commonly associated with bone marrow transplantation. Such GVH responses are associated with high fatality.
14 Related to GVH is the more common occurrence of a self-limited GVH response following ABO-compatible, but nonidentical (e.g., O to A) transplantation, manifested by hemolytic anemia (destruction of recipient type blood cells by donor immune system). More interesting, the recipient's blood type may switch to the donor's type, and later revert to recipient type. 15 Such a switch may be associated with immunological tolerance and demonstrates the potential importance of the large contribution of donor cells associated with liver transplantation. 15 These observations, incompletely understood, are the topic of this brief article.
CELLULAR BASIS OF LIVER TRANSPLANT REJECTION
The most common type of rejection seen after liver transplant surgery is acute rejection, which is characterized histologically by lymphocyte infiltration of the portal tracts, bile duct injury, and inflammation of the portal and hepatic vein endothelium. Eosinophils may also be present. The current grading scheme for mild, moderate, and severe rejection is based on Banff criteria. 16 The principal mechanism underlying acute rejection is believed to be the T lymphocyte because CD4þ and CD8þ T cells and macrophages are the dominant cell type in the infiltrates. 16, 17 Nevertheless, there may be components of natural killer (NK) cell activity and B-cell contribution to the process, especially when C4d is found on endothelial cells of biopsies during rejection.
The principal target for acute rejection is presumably the major histocompatibility complex (MHC) antigen system, as is the case with other organ transplants, although there has not been consistent correlation to date between acute rejection and degree of HLA matching in human liver transplants. In rodents, the MHC type of the donor and recipient do determine the tempo and outcome of unmodified rejection. The expression of MHC antigens by hepatocytes is limited to low levels of MHC class I and no class II. Biliary epithelial cells, which make up 3% of the nonparenchymal cells of liver constitutively, express MHC class I but not class II; however, during inflammation, MHC class I is upregulated and class II expression is induced.
Although not typically discussed in the context of transplantation due to its minor role in kidney transplant rejection, HLA-C is recognized by one of the two types of 2D killer immunoglobulin-like receptors (KIRs). These receptors are present on natural killer (NK) cells and a subset of T cells and influence cytotoxic function. [18] [19] [20] [21] Ligation of KIRs is either inhibitory or activating for NK cells, depending on whether the cytoplasmic tail is long (L, inhibitory) or short (S, activating). The HLA-C alleles, termed either group 1 (HLA-C1) or group 2 (HLA-C2) depending on which KIR they recognize, and more than 250 HLA-C allotypes fall into either group 1 or 2. 22 There has been no significant correlation of KIR genes or HLA-C type with renal transplant outcomes in reported literature. 23 However, acute rejection has been associated with the KIR genotype. 24, 25 Recent analysis of 416 liver transplant patients from the Birmingham, England group showed a striking role for the donor HLA-C genotype. 26 Patients were assigned to either the HLA-C1 or the HLA-C2 group as defined by KIR specificity. Patients whose donors were heterozygous for an HLA-C2 allele had 15.6% greater graft survival at 10 years compared with HLA-C1 patients (P ¼ 0.004). Patients whose donors were homozygous for group C2 alleles had 26.5% greater graft survival at 10 years compared with patients whose donors were homozygous for group C1 alleles (P < 0.001). In trying to assess which diagnoses of graft failure were influenced by the donor C2 genotype, it appeared that both chronic rejection and late cirrhosis were less common in recipients of C2 donor livers. In contrast, hepatic artery thrombosis was unaffected. 26 Interestingly, neither the recipient HLA-C genotype nor the match between donor and recipient HLA-C genotype influenced graft survival. HLA-A, B, and DR matching were also not of consequence. Given that HLA-C2 provides a stronger inhibitory signal to NK cells than HLA-C1 binding, the authors propose that the mechanism of their observation is via inhibition of host NK cell function and a consequent reduction in graft inflammation and injury. 26 The authors further found that presence of absence of acute rejection had no influence on long-term graft survival. Their findings with respect to HLA-C2 and the link to KIR ligands and NK cell biology may be related to the fact that the liver's lymphoid cells are composed of > 40% NK cells compared with $13% in peripheral blood. 27 It is also important to note that 60% of individuals (i.e., potential donors) possess the HLA-C2 genotype (either heterozygous or homozygous), and the remaining 40% express the homozygous HLA-C1 genotype. This interesting study would benefit from repeating on a larger scale in a different patient population, and its implications should be considered with respect to liver allocation.
Liver sinusoidal endothelial cells (LSECs), which compose 60% of the nonparenchymal cells of the liver, express MHC class II, CD40, CD80, and CD86 and are capable of antigen presentation to CD4þ and CD8þ T cells leading to tolerance or rejection in mice. 28, 29 These cells function to scavenge physiological wastes and foreign particles such as virus, lipopolysaccharide, and foreign antigens absorbed through the gastrointestinal tract, comprising an important part of the innate immune response. 30 Liver sinusoidal endothelial cells differ from vascular endothelial cells in phenotype and function (Table 1) . When mouse LSECs present antigen to CD8þ T cells, the T cells fail to develop into cytotoxic T cells. 29 As hepatocytes are surrounded by LSECs on the vascular side, it may be that the LSECs protect hepatocytes from immune attack by a combination of barrier and tolerogenic effects. 31 The unique microvascular architecture of the liver may therefore play an important role in its immunological features, rendering it less susceptible to rejection injury and lending it a greater propensity to tolerance. Sumitran-Holgersson et al have reported that antibodies to LSECs facilitate acute cellular rejection of liver transplants in humans by downregulating the expression of cytokine transforming growth factor (TGF)-b and upregulating alloreactive T cells. 32 Further support for the role of LSECs in protecting liver transplants from rejection comes from rat studies by Ge et al, 33 which show that preserved functional integrity of LSECs is associated with spontaneous acceptance of rat liver allografts.
The liver also contains the largest proportion of functional macrophages of any organ in the body-60% of total body macrophages are Kupffer cells (KCs) in the liver. In addition to their major role of phagocytosis, macrophages secrete cytokines that help direct the T-cell immune response. One of the clinical implications of end-stage liver failure is loss of clearance function by hepatic KCs and increased propensity to develop spontaneous bacterial peritonitis and overall immune incompetence, resulting in difficulty clearing infection. With respect to immune responses following liver transplant surgery, the KCs may function as antigen-presenting cells that are directly recognized by host T cells and interact with recipient T cells that migrate into the liver graft. Chen et al showed, in a rat liver transplant model with spontaneous graft acceptance and apoptosis of recipient T cells, that destruction of graft KCs using gadolinium trichloride (GdCl 3 ) decreased T-cell apoptosis and shortened survival of allografts. 34 Furthermore, their study showed that the KC-induced apoptosis of T cells was mediated via the Fas/FasL pathway, which could be directly blocked by anti-FasL antibodies. In this rat model using outbred Sprague-Dawley rats and nonarterialized liver transplants, KCs were shown to activate and induce apoptosis of T cells via increasing nuclear factor kappa B (NF-KB) activity in KCs, which elevated FasL levels in KCs and increased interleukin (IL)-4 levels in KCs; this property was associated with spontaneous tolerance. 34 Dendritic cells (DCs) and regulatory T (T reg ) cells have been linked to development of transplant tolerance through regulation of the immune response. Thomson's laboratory has studied the role of plasmacytoid DCs in liver transplant tolerance in children by evaluating B7 coregulatory molecule expression on circulating DC subset precursors. Tokita et al from this group reported recently that the ratio of plasmacytoid-to-myeloid precursor DCs (pDC:mDC ratio) was elevated in both tolerant and progressively weaning patients compared with patients maintained on immunosuppressive therapy. 35 Also, T reg frequencies, defined as CD4CD25þ FoxP3þ cells by flow cytometry, were elevated in tolerant recipients compared with either weaning or maintenance immunosuppression patients. Interestingly, the expression of programmed death ligand-1 (PD-L1) was increased on precursor plasmacytoid DCs-as evidenced by a significantly higher PD-L1:CD86 ratio-in tolerant patients compared with the other two groups. These observations suggest a possible relationship between liver transplant tolerance and high expression of the co-inhibitory molecule PD-L1 on precursor plasmacytoid DCs. For a detailed review of DCs and their possible role in liver transplantation, see elsewhere. 36 In a further study of the role of host antigenpresenting cells (APCs) in the development of liver transplant tolerance, Toyokawa et al 37 focused on the indirect pathway of allorecognition. This group depleted host APCs with phagocytic activity (cluster domain CD68þCD163þ macrophages, CD11cþ DCs) using liposome-encapsulating clodronate (LP-CL). Treatment with LP-CL abrogated tolerance to liver transplants (reduced from 100 to 43%), reduced helper T cell (T h ) 1 cytokine upregulation, permitted mild acute allograft rejection, failed to maintain donor MHC class IIþ leukocytes, and developed chronic rejection. This study suggests an important role of host phagocytic activity in the development of spontaneous tolerance in rat liver transplantation. 37 More recently, the role of hepatic stellate cells (HSCs; also known as lipocytes, fat-storing cells, and Ito cells) in immune modulation has been studied in transplant models. Hepatic stellate cells were originally known to play a role in hepatic regeneration as well as vitamin A storage. 38 A retrospective study has shown a protective mechanism of activated HSCs during acute rejection episodes in human liver transplant patients. 39 Yu and colleagues showed activated HSCs efficiently inhibited T-cell response in vitro through B7-H1. 40 In their follow-up study, they showed a beneficial effect of cotransplanted HSCs on islet transplantation, whereas HSCs derived from B7-H1 knockout mice abrogated the protective effect. 41 It is known that HSCs undergo activation through exposure to various cytokines derived from activated T cells. 42 On activation, HSCs upregulate inhibitory (B7-H1) surface molecules as well as suppressive cytokines (TGF-b). Apparently, these inhibitory molecules override the effector function of activated (or alloreactive) T cells. Indirect inhibition of T-cell activation has also been considered. FoxP3þ T reg cells have been preferentially induced in the presence of HSCs compared with DCs (personal communication with Dr. Grakoui, Emory University).
Although many studies of liver transplant immunity and tolerance do not include comparison with kidney or heart transplantation, a recently published study from Oxford evaluated the role of adoptively transferred CD8þ T cells responsive to the donor alloantigen H2Kb. 43 After transfer of 6 Â 10 6 CD8þ T cells to T-cell-depleted syngeneic recipient mice, liver allografts were spontaneously accepted long term, whereas kidneys and hearts acutely rejected. 43 The entire H2Kb-reactive T-cell pool proliferated and differentiated into memory T cells or effector T cells within 5 days of liver transplant surgery and were detectable in the lymph node and the liver. Nevertheless, grafts became tolerant, and these cells were subsequently depleted, suggesting that despite initial activation and differentiation, liver transplant leads to clonal exhaustion or depletion of alloreactive CD8þ T cells. This is in contrast to kidney and heart transplants, where passive transfer to the same cells leads to acute rejection. 43 This concept of immune exhaustion following liver transplant has been put forward previously by Alex Bishop using a rat liver transplant model, 44 and condoned by Starzl as a mechanism of liver transplant tolerance perhaps in humans. 14 
HUMORAL BASIS OF LIVER ALLOGRAFT REJECTION
Early observations in liver transplantation led some to state that the liver was not susceptible to hyperacute rejection at all. 45 However, in an adequately sensitized animal model, hyperacute rejection of liver did indeed occur and was characterized by bleeding from the liver surface, mottling of the liver, neutrophil infiltration, hemorrhage, and bile duct proliferation. 8 Although hyperacute rejection of human liver transplants is rare, it was described first by Ratner and colleagues. 46 It remains true that the liver is relatively resistant to hyperacute rejection compared with other organs, such as the kidney, and in fact sensitized patients who would be expected to undergo hyperacute rejection of a kidney can usually be desensitized by simultaneous liver/kidney transplant without humoral injury to the kidney. 47 This scenario is not assured however, as antibody-mediated rejection of the liver and/or kidney may occur if the antibody titer is sufficiently high. In humans, ABOincompatible liver transplantation and HLA-sensitized liver transplantation generally are associated with more bleeding intraoperatively, requiring more blood transfusions and longer operative time. Graft survival is somewhat worse than with ABO-compatible and nonimmunized recipients, although the disparities are not as profound as in kidney transplantation. Splenectomy and/ or plasmapheresis may be therapeutic.
Why the liver is less susceptible to antibodymediated injury has escaped satisfactory explanation to date. Several ideas have been advanced, including the notion that liver secretes soluble MHC class I, that the liver is capable of rapid repair, that its cells are relatively protected from direct immune injury, and that cells within the liver inactivate potential immune effector cells. Some of these ideas have been discussed previously in the section titled ''Cellular Basis of Liver Transplant Rejection.'' Although the notion of soluble MHC antigen seems attractive, and certainly the liver does produce soluble MHC class I antigen, 48, 49 investigators have had a difficult time finding a mechanistic link between soluble MHC class I antigen and tolerance.
Given the low concern for antidonor alloantibody, pretransplant measurement of sensitization has been largely ignored in liver transplantation, and there is little data regarding the influence of panel reactive antibody (PRA) or either T-or B-cell crossmatch results in liver transplantation. In general, a T-cell crossmatch is done only retrospectively if at all, not only because of its small clinical significance, but also because patient selection is not dependent on a negative crossmatch.
It is not clear whether alloantibody contributes to chronic rejection of liver because chronic rejection is a rare event in human liver transplantation (2% incidence overall) and the topic has not been well studied. Histologically, chronic rejection of liver is characterized by foam cells, paucity of bile ducts, and absence of significant cellular infiltrate. Clinically, it is characterized by hyperbilirubinemia and poor response to steroids or Tcell antibody therapy (but good response to tacrolimus therapy if not long-standing). The radiographic features of chronic rejection include pruning of the arborization of bile ducts and hepatic arteries. These features suggest possible participation of chronic antibody-mediated injury to the structures that best express MHC antigen in liver, but this notion remains to be tested.
The role of B-cell immunity in liver transplant tolerance is particularly obscure. Recent data on the molecular signature and cellular characteristics of tolerant kidney transplant patients suggest that immature B cells are relatively increased in representation. 50 How this relates to B-cell function and antibody production and whether it holds true for liver transplant recipients are not known. It is not known whether liver transplant recipients produce alloantibody that is innocuous, or whether antibody production is downregulated. Regardless, antibody is currently not perceived as a clinical problem in liver transplantation, in stark contrast to the considerable attention it has received in kidney transplantation due to its deleterious effects on renal allograft function. Preliminary studies have shown that in the setting of acute cellular rejection, C4d may be present in liver biopsies, 51 suggesting a concomitant component of antibody-mediated injury, but the meaning of C4d staining of liver remains unclear.
Given the likelihood that our understanding of B-cell immunity in transplantation will rapidly expand and shed light on rejection and tolerance, it seems prudent to pursue a better understanding of the role of antibody in liver transplantation. It seems unlikely that it is irrelevant or unimportant to the liver, and more likely that the liver's mechanisms to protect from antibodymediated injury may be useful as we seek approaches that could be applied to other organ transplants.
TOLERANCE IN HUMAN LIVER TRANSPLANTATION
Similar to what had been earlier reported for kidney transplantation, patients with a previous successful bone marrow transplant from an HLA-identical donor can undergo subsequent successful liver transplant surgery from the same donor with discontinuation of all immunosuppressive drugs. 52 Nonmyeloablative conditioning with stem-cell infusion, followed by liver transplant from a living donor has led to various levels of chimerism and tolerance to the liver. However, GVH usually precludes the withdrawal of immunosuppression under these regimens. Graft-versus-host response has also been a major complication of donor hematopoiesis, sometimes occurring spontaneously after liver transplant, as discussed previously for ABO-compatible but nonidentical liver transplants.
The GVH response usually results in either death of the patient or the need for ongoing immunosuppression to control GVH itself. However, a recent report from Sydney, Australia described a child who underwent a completely MHC-mismatched liver transplant (ABO compatible) with subsequent development of complete hematopoietic chimerism and tolerance 17 months after surgery without evidence of GVH. 15 The donor and recipient were blood group O, but the donor was Rh positive and the recipient was Rh negative. The recipient switched from her own blood type to the donor's type following hemolytic anemia, suggesting engraftment of donor hematopoietic stem cells from the donor liver. Chromosomal analysis of peripheral blood cells demonstrated that erythroid, myeloid, and T-and B-lymphocyte cells were all of donor type. When immunosuppression was withdrawn 4 months after onset of hemolytic anemia and 14 months after the transplant, the patient did not develop GVH or rejection and has maintained stable liver allograft function for > 5 years. 15 The baseline immunosuppression consisted of cyclosporine and prednisone, and these were weaned over a 3-month period without evidence of GVH or rejection. The patient lost antibodies to measles and mumps during withdrawal of immunosuppression but regained these after reimmunization, suggesting that the recipient's B cells, which initially produced antibody, were lost and later replaced by donor-derived naïve B cells. Analysis of levels of T-cell receptor excision circles, markers of early T cells derived from thymus, suggested thymic engraftment of donor lymphocytes rather than their peripheral expansion. Finally, mixed lymphocyte culture 5 years after the transplant showed donor-specific unresponsiveness with intact third-party response. 15 This case report, while fascinating, is also highly unusual in that central tolerance with replacement of thymic precursor T cells with cells of donor origin occurred following self-limited hemolytic anemia (a clinically mild variant of GVH), and the source of the donor cells was clearly the liver as the patient never received a bone marrow transplant. The patient resembles children who have undergone bone marrow transplant for malignancies and who receive nonmyeloablative therapy. Such complete hematopoietic chimerism is highly unusual following solid organ transplant and likely is related to the facts that the organ transplanted was liver and that the recipient was a child. The complete chimerism that occurred in this child is no doubt responsible for the state of tolerance achieved. Although mixed or partial chimerism is not uncommon after liver transplant, its role in tolerance and rejection is less clear, correlating with either condition. [53] [54] [55] [56] [57] The challenge of this particular case report is that the immunological circumstances occurred spontaneously and could neither have been predicted nor reproduced in another patient in a planned manner.
Although children would potentially benefit the most from immunological tolerance following liver transplant surgery, they also have one of the highest rates of noncompliance with drug therapy during the transition to adulthood (approximately ages 17 to 22 years) and have therefore provided clinicians with observations regarding discontinuation of immunosuppressive drug therapy. In a report retrospectively reviewing 111 adolescent patients (ages 12 to 21 years) at least 6 months following liver transplant, Berquist et al found that fully 45% of patients either did not take immunosuppressive drugs or did not attend any clinic for 1 year. 58 Nonadherence to immunosuppressive drug therapy and noncompliance with laboratory testing were significantly associated with rejection episodes in 31 patients (P < 0.007) but not in a subgroup of 7 patients who completely stopped their immunosuppression. The rate of rejection in the nonadherent group was 33.3% compared with 9.3% in children who adhered to immunosuppressive drug therapy. Furthermore, although seven patients apparently did not reject despite being off drugs during the study's observation period, the long-term consequences of drug discontinuation are not known for these patients because the follow-up was limited to 1 year and was not the primary focus of the report. The other obvious problem with discontinuation of drug is the inability to predict which patients will reject versus those who will not. Studies such as this of noncompliance as an approach to tolerance suggest that it is highly risky to discontinue immunosuppressive drugs, particularly in the absence of careful clinical monitoring of graft function. Although the rarer clinical ''successes'' of tolerance are fascinating, the more common failures can be devastating. Some reports also indicate that withdrawal of therapy may increase the risk of recurrent disease. 59 Mazariegos et al from the University of Pittsburgh have considerable experience monitoring children who have either intentionally or from noncompliance withdrawn from immunosuppressive therapy after liver transplant. 60 This group initially reported on a group of patients withdrawn from drugs after either EpsteinBarr virus (EBV) infection or post-transplant lymphoproliferative disease (PTLD). 61, 62 Another group was reported to have discontinued drugs due to noncompliance, 63 and a final group was withdrawn in a planned manner to evaluate the potential success rate of intentional drug weaning. 64, 65 Table 2 shows the summary of these patients.
Of note is that in the Pittsburgh series of 18 patients initially reported as doing well following immunosuppressive drug withdrawal, 6 have subsequently died. Two deaths were associated with poor liver function-one due to recurrent alcoholism and one because of recurrent hepatitis C cirrhosis. The remaining four deaths occurred in the setting of normal liver function and were attributed to C. difficile colitis after undergoing renal transplant and restarting immunosuppression, cerebrovascular Six of the 18 original tolerant patients have died. An additional 16 patients have subsequently been completely weaned from IS. Thirteen patients weaned off IS infection and 6 noncompliant patients are also being followed. The mean and median ages at transplant, time from transplant to wean initiation, time from initiation of wean to complete IS withdrawal, and current time off IS are shown. accident, and sepsis. An additional 16 patients were weaned from immunosuppression (total of 28 patients from Table 2) , and these required a mean time of 5.7 years from transplant to the time of weaning and 2.2 years to complete drug withdrawal. Most of the weaned patients (22 of 28) were children (mean age 3.8 years, range 0.1 to 49.9 years) transplanted before age 18. 60 All were recipients of deceased donor grafts.
Emergent immunosuppressive drug withdrawal in the setting of EBV infection or PTLD was reported in 13 patients by Mazariegos et al in a cohort of young children with mean age at liver transplant of 3.5 years (range 0.4 to 16.3 years). These patients were weaned earlier after liver transplant surgery than the electively weaned patients (3.1 years versus 5.7 years). These patients have remained drug free for an average of 11.7 years (range 4.6 to 15.7 years). Patients in the Pittsburgh series who were noncompliant but without rejection (n ¼ 6) withdrew their immunosuppressive drugs at a mean of 7.3 years after liver transplant and were reported to be off all drugs for a mean of 17.1 years (range 6.9 to 24.7 years).
An observation of the Pittsburgh group that differs from most series is that patients with previous EBV infection or PTLD can remain indefinitely off immunosuppression. Most such patients in the authors' experience require reinstitution of at least low-dose steroids and/or a calcineurin inhibitor to avoid (or treat) rejection. However, other groups have also reported drug-free stable graft function after PTLD in 20 to 43% of cases. 66, 67 The Pittsburgh group also cautions against drug withdrawal in patients with an underlying liver disease of hepatitis C given the difficulty of interpreting elevated liver enzymes during withdrawal. The suggestion is made by Mazariegos et al that living donor transplants may be more amenable to drug withdrawal, although the data on the Pittsburgh experience in this area are not published. Finally, these authors suggest that drug withdrawal is not advisable when the underlying liver disease is of an autoimmune etiology because of the propensity for recurrence of original disease, as this stopped withdrawal in some of the Pittsburgh patients.
Notably, the 10-year follow-up of the Pittsburgh patients suggests that patients withdrawn from immunosuppression without rejection after 2 years are unlikely to develop later acute rejection.
Kawasaki et al have reported successful immunosuppressive drug withdrawal following living donor liver transplantation in Japan. 68 Most of these cases involved haploidentical donor-recipient pairs, typically parent to child. The favorable MHC matching would logically benefit such a strategy. These patients were reported to have developed evidence of T reg cells as a mechanistic basis for their tolerance. 69 
TOLEROGENIC IMMUNOSUPPRESSIVE PROTOCOLS FOR LIVER TRANSPLANTATION
Currently, there is no evidence that a particular immunosuppressive protocol in liver transplantation is more likely to lead to successful development of tolerance after transplant surgery. The most commonly used immunosuppressive protocol in the United States for liver transplantation is based on tacrolimus (Scientific Registry of Transplant Recipients [SRTR] report), and Lake et al have reported that the combination of tacrolimus and mycophenolate mofetil is associated with the most favorable outcomes after liver transplant surgery. 70 In general, antibody-depleting agents such as thymoglobulin or alemtuzumab have not been broadly applied after liver transplant due to the inherent increased risk of infection in these patients, who are at greater risk of infection than kidney transplant recipients (who appear to benefit from the profound early immunosuppression offered by these agents). 71, 72 Although peripheral immune cell depletion may offer an advantage in subsequent development of tolerance, and this strategy is being evaluated in current trials (e.g., the Immune Tolerance Network [ITN]-sponsored trial in the United States), the risk of depletion may outweigh the potential benefit in liver transplant patients.
Costimulation blockade targeting either the CD28/B7 pathway of activation or the leukocyte function-associated antigen (LFA)-1/intercellular adhesion molecule (ICAM) pathway may be promising for liver transplantation and is the subject of ongoing clinical trials. However, neither of these strategies has demonstrated potential for liver transplant tolerance in humans at this time.
In general, it would appear that the unusual and sporadic cases of liver transplant tolerance have not been linked to a particular immunosuppressive strategy, either with respect to induction or to maintenance immunosuppressive therapy. The mechanisms underlying liver transplant tolerance do not appear to be either prevented or condoned by a particular regimen based on current clinical cases reported.
IMMUNOLOGICAL MONITORING OF TOLERANCE IN LIVER TRANSPLANTATION
Monitoring liver transplant patients with respect to rejection or its absence continues to rest on measurement of aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase, gammaglutamyl transpeptidase (GGT), and bilirubin-all measuring proteins made in the liver and reflecting hepatocyte and biliary canalicular function, and none measuring immune status. When these liver tests are significantly elevated over baseline, a biopsy may be performed, which is a sensitive and specific indicator of THE LIVER AND TRANSPLANTATION TOLERANCE/KNECHTLE, KWUN rejection, albeit with an estimated 10% error rate due to sampling or interpretation error. Biopsy also has an estimated complication rate of $1%, mostly related to bleeding and pain.
Development of less invasive methods of immune monitoring would be attractive, and it would be beneficial to be able to test more frequently and to diagnose rejection earlier than when histological injury is already established. With respect to tolerance, it would be advantageous for the patient and physician to know when immunosuppressive drugs could be safely weaned or not. Currently, there are no validated assays to determine whether a patient is tolerant or not. Some of the approaches under evaluation as assays for rejection or tolerance include complementary (c)DNA microarray technology, and functional lymphocyte assays.
Kawasaki et al studied 11 tolerant living donor liver transplant patients. 68 Of these patients, six had electively weaned off immunosuppression without rejection, and five were removed from immunosuppression due to EBV or PTLD complications. Eight patients had an underlying etiology of biliary atresia; all of these were children with a mean age of 3 years (range, 0.7 to 12.8 years). Most were haploidentical recipients of a parent's partial liver. Microarray analysis of $12,000 genes revealed 10 genes that were markedly altered in the tolerant versus control patients and were related to immune function. These genes included STAT1, C3, CBL, ID3, IL1 a and b, IL-8, SOCS3, GR-a, and COX2. Each of these genes was also evaluated by reverse transcriptase polymerase chain reaction (RT-PCR), which correlated with microarray analysis and confirmed differences between tolerant and nontolerant liver transplant patients. 68 Monitoring T reg cells, DC subsets, and cytokine gene polymorphisms has been reported and is being evaluated for correlation with clinical outcomes of drug weaning or tolerance in liver transplantation. [73] [74] [75] [76] However, the challenge to date has been that results overlap considerably between tolerant and nontolerant patients, allowing discrimination between groups of patients but not between individual patients as would be necessary for clinical patient management.
To assess the immune function of 12 tolerant living donor liver transplant recipients, Li et al studied the frequency of CD4þCD25þ cells, B cells, and Vdelta1:Vdelta2 gamma-delta T-cell ratios and compared them to patients on maintenance immunosuppression and normal human controls. The authors found that NK and NK T cells were decreased in tolerant recipients compared with both other groups. 69 These observations are also of interest given the findings of Hanvesakul discussed previously with respect to NK cells. 26 An assay currently being studied by us to distinguish between individual patients' immune statuses is the cytokine kinetics assay originally reported by Kwun et al. 77 Beginning with a traditional mixed lymphocyte reaction (MLR), the assay readout is based on daily cytokine production by recipient lymphocytes rather than by the traditional proliferative response. The potential information could be used to decide on drug dosing. A functional T-cell assay would potentially yield information on immune function that changes over time rather than a static picture of genotype or polymorphism that might act as a risk factor.
A more sensitive assay is also needed for acute rejection in liver transplant patients. Potentially, imaging modalities such as magnetic resonance imaging (MRI) may be able to assess changes in water density (edema) and blood flow to indicate that rejection is likely. 78, 79 Again, such methods require further study.
CONCLUSION
The mechanisms of rejection of liver transplants may differ in important ways or degrees from other transplanted organs, and, similarly, tolerance may be more readily achieved in liver transplantation. Progress in understanding the immune response and how to monitor such patients will undergird new efforts to prolong allograft survival without compromising the overall health of patients. 
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